Table 1.
Demographics and overall BRCA1/2 tumor results of study population. PV, pathogenic variant; VUS, variant of uncertain significance; NEG, no reported variants; other, includes metastases, recurrence, unknown/information not provided; undetermined, primary tumor site could not be determined.
| ALL (n = 570) | BRCA1‐PV (n = 63) | BRCA1‐VUS (n = 18) | BRCA2‐PV (n = 30) | BRCA2‐VUS (n = 33) | NEG (n = 426) | |
|---|---|---|---|---|---|---|
| Age at procedure a | 63.1 | 56.8 b | 64.4 | 61.9 | 63.5 | 64.1 |
| Mean (years); range | 33–90 | 33–83 | 51–79 | 38–84 | 43–84 | 38–90 |
| Incident/prevalent | ||||||
| Incident | 256 (45%) | 27 (43%) | 10 (56%) | 12 (40%) | 13 (39%) | 194 (45.5%) |
| Prevalent | 307 (54%) | 35 (55.5%) | 8 (44%) | 18 (60%) | 20 (61%) | 226 (53%) |
| Other | 7 (1%) | 1 (1.5%) | 0 | 0 | 0 | 6 (1.5%) |
| Primary tumor site | ||||||
| Ovarian | 240 (42%) | 31 (49%) | 6 (33%) | 14 (47%) | 17 (52%) | 158 (37%) |
| Fallopian tube | 111 (19.5%) | 12 (19%) | 5 (28%) | 5 (16.5%) | 5 (15%) | 84 (20%) |
| Tubo‐ovarian | 99 (17.5%) | 8 (13%) | 4 (22%) | 5 (16.5%) | 5 (15%) | 75 (17.5%) |
| Primary peritoneal | 43 (7.5%) | 6 (9.5%) | 0 | 5 (16.5%) | 3 (9%) | 32 (7.5%) |
| Undetermined | 77 (13.5%) | 6 (9.5%) | 3 (17%) | 1 (3.5%) | 3 (9%) | 70 (18%) |
a
Age at time of procedure was used as not all samples were collected at the time of diagnosis.
b
Significantly different from the patients with mutation‐negative tumors (P < 0.001).